Clinical Coagulation, Malmö
421 – 430 of 630
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy
2009) 10th International Symposium on Myelodysplastic Syndromes In Leukemia Research 33(Suppl 1). p.49-50(
- Contribution to journal › Published meeting abstract
-
Mark
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
(
- Contribution to journal › Article
-
Mark
Characterization of a Novel Aberrant Splice Site, 79bp Downstream of Exon 5 in the Human Factor 7 Gene Detected in Patients with Severe Congenital Factor VII Deficiency.
(
- Contribution to journal › Published meeting abstract
-
Mark
Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmö Thrombophilia Study (MATS).
(
- Contribution to journal › Article
-
Mark
Physical activity as prevention of osteoporosis in patients with severe haemophilia on long term prophylaxis
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0118-0118(
- Contribution to journal › Published meeting abstract
-
Mark
Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin.
(
- Contribution to journal › Article
-
Mark
Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
Lower incidence of procoagulant abnormalities during follow-up after creation of the Fontan circulation in children.
(
- Contribution to journal › Article
-
Mark
Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis.
(
- Contribution to journal › Article
-
Mark
Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.
(
- Contribution to journal › Article